CliffBio
small molecule

DEXILANT SOLUTAB

DEXLANSOPRAZOLE

Loss of exclusivityMarch 2029latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameDEXILANT SOLUTAB
Active ingredientDEXLANSOPRAZOLE
Strength30MG
Dosage formTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
9241910March 2029product
8871273*PEDJuly 2028—
8871273January 2028product
8461187*PEDJuly 2026—
9011926February 2026product
8461187January 2026product
9238029January 2026product

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DEXILANT SOLUTAB patent cliff — loss of exclusivity March 2029 | CliffBio